Our major findings bring benefit to society, both in the UK and throughout the world. Explore our impact in the following case studies.
Preventing bone loss in patients treated for breast cancer
Our research into the link between breast cancer and bone loss led to changes in international guidelines and treatment
Almost 30,000 postmenopausal women in the UK develop breast cancer each year. Aromatase inhibitors (AIs) are a class of drug that significantly improve their survival rate.
Research undertaken by the University of Manchester confirmed, however... Read More
Improving outcomes of women diagnosed with and at increased risk of breast cancer
Over 1.5 million women who develop breast cancer each year have benefited from our research into treatment and prevention
Breast cancer is the most common cause of cancer and cancer mortality in women worldwide.
Research conducted at The University of Manchester on the treatment and prevention of breast cancer has benefited over 1.5 million women... Read More
The Development and Translation of Tamoxifen to the Clinic in Manchester
The first clinical trial of the drug was begun at the Christie Hospital, Manchester in December 1969
The Development and Translation of Tamoxifen to the Clinic in Manchester... Further Reading